** Shares of Immuron rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold
** The biopharmaceutical co hits highest level since early October
** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA
** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea
** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time
** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares
** Stock rose 2.6% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@ThomsonReuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。